Search

Your search keyword '"Wada Yoko"' showing total 11 results
Start Over Author "Wada Yoko" Journal modern rheumatology
11 results on '"Wada Yoko"'

1. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease

Author

Masaki, Yasufumi, primary, Matsui, Shoko, additional, Saeki, Takako, additional, Tsuboi, Hiroto, additional, Hirata, Shintaro, additional, Izumi, Yasumori, additional, Miyashita, Taiichiro, additional, Fujikawa, Keita, additional, Dobashi, Hiroaki, additional, Susaki, Kentaro, additional, Morimoto, Hisanori, additional, Takagi, Kazutaka, additional, Kawano, Mitsuhiro, additional, Origuchi, Tomoki, additional, Wada, Yoko, additional, Takahashi, Naoki, additional, Horikoshi, Masanobu, additional, Ogishima, Hiroshi, additional, Suzuki, Yasunori, additional, Kawanami, Takafumi, additional, Kawanami Iwao, Haruka, additional, Sakai, Tomoyuki, additional, Fujita, Yoshimasa, additional, Fukushima, Toshihiro, additional, Saito, Masatoshi, additional, Suzuki, Ritsuro, additional, Morikawa, Yuko, additional, Yoshino, Tadashi, additional, Nakamura, Shigeo, additional, Kojima, Masaru, additional, Kurose, Nozomu, additional, Sato, Yasuharu, additional, Tanaka, Yoshiya, additional, Sugai, Susumu, additional, and Sumida, Takayuki, additional

Published
2016
Full Text
View/download PDF

8. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy

Author

Kuroda, Takeshi, primary, Hirose, Shintaro, additional, Tanabe, Naohito, additional, Sato, Hiroe, additional, Nakatsue, Takeshi, additional, Ajiro, Jyunya, additional, Wada, Yoko, additional, Murakami, Syuichi, additional, Hasegawa, Hisashi, additional, Ito, Satoshi, additional, Sakatsume, Minoru, additional, Nakano, Masaaki, additional, and Gejyo, Fumitake, additional

Published
2007
Full Text
View/download PDF

9. Systemic lupus erythematosus in identical twins: a case report

Author

Kuroda, Takeshi, primary, Harada, Takashi, additional, Wada, Yoko, additional, Oyanagi, Akihisa, additional, Ohfuchi, Yuko, additional, Murakami, Syuichi, additional, Hirose, Shintaroh, additional, Hasegawa, Hisashi, additional, Nakano, Masaaki, additional, and Gejyo, Fumitake, additional

Published
2005
Full Text
View/download PDF

11. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease.

Author

Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, Miyashita T, Fujikawa K, Dobashi H, Susaki K, Morimoto H, Takagi K, Kawano M, Origuchi T, Wada Y, Takahashi N, Horikoshi M, Ogishima H, Suzuki Y, Kawanami T, Kawanami Iwao H, Sakai T, Fujita Y, Fukushima T, Saito M, Suzuki R, Morikawa Y, Yoshino T, Nakamura S, Kojima M, Kurose N, Sato Y, Tanaka Y, Sugai S, and Sumida T

Subjects
Adult, Aged, Dose-Response Relationship, Drug, Drug Dosage Calculations, Drug Monitoring, Female, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Humans, Male, Middle Aged, Prospective Studies, Remission Induction methods, Treatment Outcome, Hypergammaglobulinemia blood, Hypergammaglobulinemia diagnosis, Hypergammaglobulinemia drug therapy, Immunoglobulin G immunology, Prednisolone administration & dosage, Prednisolone adverse effects
Abstract

Objective: Although glucocorticoids are effective for patients with IgG4-related disease, the treatment has not yet been standardized. Therefore, the treatment strategy should be established., Patients and Methods: Patients who fulfilled the comprehensive diagnostic criteria for definite IgG4-related disease were started on prednisolone (0.6 mg/kg body weight) with the dose reduced every two weeks. The subsequent maintenance dose and need for prednisolone were determined for individual patients. The primary endpoint was the complete remission (CR) rate at one year. Secondary endpoints included overall response rate (ORR), the maintenance dose, the relapse rate, and adverse events., Results: This study enrolled 61 patients. After clinicopathological review, three patients were excluded, and one, 13, and 44 patients were diagnosed with probable, possible, and definite IgG4-related disease, respectively. Of the 44 patients with definite IgG4-RD, 29 (65.9%) achieved CR, and the ORR was 93.2%. No patient was refractory to primary treatment. The most frequent adverse events were glucose intolerance. Six patients relapsed., Conclusions: Glucocorticoid treatment is usually effective for patients with IgG4-RD, and we should examine the possibility of other disorders when a patient is glucocorticoid refractory. Some patients are misdiagnosed, making central clinicopathological review of diagnosis very important in conducting clinical studies.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results